Andere talen Agios Pharmaceuticals, Inc.

Aandelen

AGIO

US00847X1046

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
31,49 ^USD	-0,57%		+6,64%	+41,40%

16/02	AGIOS PHARMACEUTICALS, INC. : Een koopadvies van RBC Capital Markets	ZM
15/02	Agios Pharmaceuticals, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024	18/04
Agios Publishes 2024 Environmental, Social and Governance Report	10/04
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report	09/04
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	06/03
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	05/03
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024	22/02
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises	15/02
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	15/02
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Servier replonge dans le rouge en raison du dossier Mediator	07/02
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024	02/02
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing	09/01
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	08/01
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	08/01
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints	03/01
Agios Pharmaceuticals : ENERGIZE Phase 3 Topline Results	03/01
Agios' blood disorder drug meets goals of late-stage study	03/01
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	03/01
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	03/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Agios Pharmaceuticals, Inc.

Aandelen

AGIO

US00847X1046

Andere talen

Filters